You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

HCV Experimental Treatments
Alphabetical Order
  ABT-450
  Albumin Interferon
  Alisporivir (Debio 025)
  ANA773 and ANA598
  BI 201335 and BI 207127
  BMS-650032, BMS-790052 and BMS-824393
  Boceprevir (aka Victrelis)
  Cyclophilin Inhibitor SYC-635
  Danoprevir (aka RG7227/ITMN-191)
  GI-5005
  GS 9132, GS 9190 (Tegobuvir)and GS 9450
  IDX136, IDX316, IDX320, IDX375 and IDX184
  IMO-2125
  Locteron (Interferon)
  MK-5172, MK-0608 and MK-70099
  Narlaprevir
  Nitazoxanide
  Pegylated Interferon Lambda
  PSI-879, PSI-7851, PSI-7977, PSI-9388
  Sorafenib (Nexavar)
  Telaprevir (Incivek)
  TMC435
  VCH-759, VCH-916 and VCH-222
  Viramidine (aka Taribavirin)

 


ABT-450       TOP
4-Week Virologic Response and Safety of ABT-450 Given with Low-dose Ritonavir (ABT-450/r) First As 3-Day Monotherapy Then in Combination with Pegylated Interferon Alpha-2a and Ribavirin (SOC) in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects
Initial Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450 When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary Results of Study M11-602 in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects

Albumin Interfern        TOP
Human Genome Sciences Announces FDA Is Unlikely to Approve Albumin Interferon Once Every 2 Weeks
6/22/2010
Human Genome Sciences Submits FDA Licensing Application for Albumin Interferon (Zalbin) for Chronic Hepatitis C
12/08/09
Albumin Interferon (Albuferon) and HCV Polymerase Inhibitor PSI-7851 Advance in Clinical Trials
7/03/09
Review Finds Albumin Interferon for Chronic Hepatitis C Is Effective and Well-tolerated; Phase 3 Results Show Non-inferiority to Pegylated Interferon
3/20/09
New Hepatitis C Treatment Trials: HCV Polymerase Inhibitor R7128, Nucleotide Prodrug IDX184, and Albumin Interferon (Albuferon)
1/20/09
Albumin Interferon (Albuferon) Administered Once Every 2-4 Weeks May Be As Effective as Once-weekly Pegylated Interferon
9/23/08
Safety and Activity of Once-Monthly Albinterferon Alfa-2b (Albuferon) in Genotype 2/3 Chronic Hepatitis C Patients
5/23/08
Antiviral Activity, Pharmacodynamics, and Quality of Life in Genotype 1 Hepatitis C Patients Treated with Albinterferon (Albuferon)
5/23/08
Albuferon Dose in Ongoing Trials is Lowered Due to Safety Concerns
1/25/08

Alisporivir (Debio 025)        TOP
Cyclophilin Inhibitor Alisporivir Active Against HCV in Phase 2b, HBV in Lab
4/08/2011
Debiopharm Licenses Cyclophilin Inhibitor Alisporivir (Debio 025) for Hepatitis C
2/12/2010
Debiopharm Begins Randomization of Participants in Phase 2b Trial of Cyclophilin Inhibitor Debio 025 for Chronic Hepatitis C
2/03/09
Cyclophilin Inhibitor Debio-025 Demonstrates Potent Anti-HCV Activity in HIV-HCV Coinfected Patients
3/14/08

ANA773 and ANA598        TOP
Anadys Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598
2/01/2011
First Cohort Dosing Completed in Clinical Trial of HCV Polymerase Inhibitor ANA598
2/02/2010
First Participants Treated in Phase 2 Trial of Anadys HCV Polymerase Inhibitor ANA598
9/15/09
Experimental Interferon-inducer ANA773 Demonstrates Antiviral Activity In Hepatitis C Treatment Trial
8/21/09
Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09

BI 201335 and BI 207127        TOP
BI201335 Shows Potent Activity against HCV
BI 201335 for Hepatitis C Moves into Phase 3 Trials
4/29/2011
Direct-acting Drug Combos Suppress HCV without Interferon, but Resistance Remains a Concern
11/15/2010
Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5 days’ monotherapy
11/02/2010
Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin, in patients with chronic hepatitis C: the SOUND-C1 trial
11/02/2010
Virological response and safety of 4 weeks’ treatment with the protease inhibitor BI 201335 combined with 48 weeks of peginterferon alfa 2a and ribavirin for treatment of HCV GT-1 patients who failed peginterferon/ribavirin
11/02/2010
Experimental HCV Protease Inhibitor BI 201335 Shows Robust Antiviral Activity in Genotype 1 Non-responders
4/23/2010
Experimental HCV Protease Inhibitor BI 201335 Demonstrates Promising Results in Combination with Pegylated Interferon and Ribavirin
11/06/09
SILEN-C1: Early Antiviral Activity and Safety of BI 201335 Combined with Peginterferon alfa-2a and Ribavirin in Treatment-naïve Patients with Chronic Genotype 1 HCV infection
11/06/09
Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin
11/06/09
Investigational HCV Protease Inhibitor BI 201335 Exhibits Promising Antiviral Activity
11/11/08
Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-na´ve patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R)
11/05/08
Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection
11/05/08

BMS-650032, BMS-790052 and BMS-824393        TOP
BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
4-12-2011
BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
4-12-2011
Company Collaboration to Test BMS-790052 + PSI-7977 Combo for Hepatitis C
1-14-2010
Direct-acting Drug Combos Suppress HCV without Interferon, but Resistance Remains a Concern
11/15/2010
BMS-790052, a First-in-Class Potent Hepatitis C Virus NS5A Inhibitor, Demonstrates Multiple-Dose Proof-of-Concept in Subjects With Chronic GT1 HCV Infection
11/02/2010
Coadministration of BMS-790052 and BMS-650032 Does Not Result in a Clinically Meaningful Pharmacokinetic Interaction in Healthy Subjects
11/02/2010
Pipeline Asset Update for BMS-790052 (NS5A inhibitor) and BMS-650032 (NS3 inhibitor)
11/02/2010
Combination Therapy With BMS-790052 and BMS-650032 Alone or With Pegylated Interferon and Ribavirin (pegIFN/RBV) Results in Undetectable HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1 Null Responder
11/02/2010
BMS-824393 Is a Potent Hepatitis C Virus NS5A Inhibitor With Substantial Antiviral Activity When Given as Monotherapy in Subjects With Chronic G1 HCV Infection
HCV NS5A Inhibitor BMS-790052 Suppresses Viral Replication in Combination with Pegylated Interferon/ribavirin
4/28/2010

Boceprevir (aka Victrelis)        TOP
Boceprevir (Victrelis) Approved for Hepatitis C
5-17-2011
Boceprevir for HCV Wins Unanimous FDA Committee Recommendation
4-29-2011
FDA Hearings Next Week on Boceprevir and Telaprevir for HCV
4-23-2011
Boceprevir Improves Response to Interferon-Based HCV Therapy
4-1-2011
FDA Committee Sets Review Dates for HCV Drugs Boceprevir and Telaprevir
3-18-2011
HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and Non-responders
3-15-2011
HCV Protease Inhibitor Boceprevir Accepted for Priority Review in U.S. and Europe
1-14-2010
Boceprevir Improves Response to Interferon-based Therapy and Allows Many Patients to Reduce Duration
11/02/2010
HCV RESPOND-2 Final Results High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re- Treated with Boceprevir Plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin
11/02/2010
Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with HCV Genotype 1
11/02/2010
Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1)
11/02/2010
Hemoglobin Decline During Lead-in Phase as an Early Predictor of Anemia After the Addition of Boceprevir: A Retrospective Analysis of HCV SPRINT-1
11/02/2010
Response-Guided Therapy with Boceprevir + Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with Hepatitis C Virus Genotype 1 Was Similar to a 48-Wk Fixed-Duration Regimen with Boceprevir + Peginterferon alfa-2b/Ribavirin in SPRINT-2
11/02/2010
HCV Protease Inhibitor Boceprevir Increased Sustained Response to Interferon-based Therapy in Phase 3 Studies
8/06/2010
Hope Against Hepatitis C
7/23/2010
HCV Protease Inhibitor Boceprevir Demonstrates Durable Sustained Response with No Late Relapse
4/28/2010
SPRINT-1 Study Shows Benefits of Response-guided Therapy with Experimental HCV Protease Inhibitor Boceprevir
11/06/09
Response-Guided Therapy for Boceprevir Combination Treatment? Results from HCV SPRINT-1
11/03/09
Schering-Plough Completes Enrollment of Phase 3 Trials of Boceprevir for Chronic Hepatitis C
6/26/09
Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity
5/01/09
Adding Boceprevir to PegIntron/Ribavirin Significantly Improves Sustained Virological Response in Chronic Hepatitis C Patients
5/01/09
SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS
5/01/09
HCV SPRINT-1 Final Results SVR 24 Boceprevir* plus PegIFN alfa-2b/Ribavirin HCV 1 Treatment Na´ve Patients
5/01/09
Preclinical Characterization of SCH 900518, A Novel Mechanism-Based Inhibitor of HCV NS3 Protease
4/24/09
A Regional Gastrointestinal Absorption Study of the HCV NS3 Protease Inhibitor SCH 900518 in Healthy Volunteers
4/24/09

GI-5005       TOP
Preliminary Results Show Promising Response to Therapeutic Hepatitis C Vaccine GI-5005
11/09/2010
HCV Therapeutic Vaccine GI-5005 Improves Rate of Sustained Response to Interferon-based Therapy for Hepatitis C
11/09/2010
Researchers Report Promising Results from Studies of 3 Therapeutic HCV Vaccines
5/19/2009

GS 9132 and GS 9190 (Tegobuvir) and GS 9450        TOP
Tegobuvir Works Well in Triple and Quad Regimens for HCV
4/23/2010
Gilead Terminates Study of Caspase Inhibitor GS 9450 for Hepatitis C Due to Safety Concerns
4/20/2010
Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09
Safety, Tolerability, and Pharmacokinetics of GS-9450 in Healthy Male and Female Volunteers
4/24/09

IDX136, IDX316, IDX320, IDX375 and IDX184        TOP
FDA Suspends Trials of Experimental HCV Regimen IDX184 plus IDX320 Due to Liver Toxicity Concerns
9/10/2010
Idenix Begins Proof-of-Concept Study of HCV Protease Inhibitor IDX320
6/18/2010
HCV Polymerase Inhibitor IDX184, Protease Inhibitor IDX320, and Triple Combination Show Promising Antiviral Activity
5/04/2010
Vertex, InterMune, and Idenix Present Hepatitis C Drug Development Updates at Investor Conference
1/22/2010
IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor: Results of a First-in-Man Safety and Pharmacokinetic Study
5/01/09
Antiviral Activity of the Liver-Targeted Nucleotide HCV Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside Metabolite in HCV-infected Chimpanzees
5/01/09
Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor
4/24/09
Preclinical Profiles of IDX136 and IDX316, Two Novel Macrocyclic HCV Protease Inhibitors
4/24/09

Locteron (Interferon)        TOP
Controlled Release Interferon (Locteron) Every 2 Weeks Works as Well as Pegylated Interferon but with Fewer Side Effects
5-18-10
OctoPlus Initiates Phase IIa Study of Locteron Controlled-release Interferon
2-22-08

IMO-2125        TOP
Toll-like Receptor Antagonist IMO-2125 Stimulates Production of Natural Interferons with Activity against Hepatitis C Virus
12/13/09
Idera Pharmaceuticals Begins Phase 1 Trial of Toll-like Receptor Agonist IMO-2125 for Chronic Hepatitis C
10/13/09

MK-5172, MK-06080 and MK-7009        TOP
Safety and Antiviral Activity of MK-5172, a Novel HCV NS3/4a Protease Inhibitor with Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients
11/09/2010
Safety, Tolerability, and Pharmacokinetics after Single and Multiple Doses of MK-5172, a Novel HCV NS3/4a Protease Inhibitor with Potent Activity Against Known Resistance Mutants, in Healthy Subjects
11/09/2010
Sustained Viral Response (SVR) Rates in Genotype 1 Treatment-naïve Patients with Chronic Hepatitis C (CHC) Infection Treated with Vaniprevir (MK-7009), a NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days
11/09/2010
Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09
MK-7009 Significantly Improves Rapid Viral Response (RVR) in Combination with Pegylated Interferon Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C (CHC) Genotype 1 Infection
4/24/09


Narlaprevir
       TOP

Boosted Narlaprevir plus Pegylated Interferon and Ribavirin Leads to Rapid Viral Suppression in Genotype 1 Hepatitis C Patients
11/10/09

Nitazoxanide        TOP
Nitazoxanide Increases Response to Pegylated Interferon plus Ribavirin in Treatment-naive and Non-responder Hepatitis C Patients
5-28-2010
Nitazoxanide plus Pegylated Interferon and Ribavirin Produces Virological Response in Some Prior Non-responders with Cirrhosis
11/10/09
Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents
12/08/08
Nitazoxanide Added to Standard Therapy Improves Response in Patients with Genotype 4 HCV: STEALTH-C1 Study
5/08/08

Pegylated Interferon Lambda        TOP
Pegylated Interferon Lambda Boosts Response with Few Side Effects
4-5-2011
Pegylated Interferon Lambda for Hepatitis C Produces Good Response with Minimal Blood Toxicity
12/10/2010
The Effect of Treatment Group, HCV Genotype, and IL28B Genotype on Early HCV Viral Kinetics in a Phase 2a Study of PEG-Interferon Lambda (pegIFNë) in Hepatitis C Patients
11/09/2010
Pegylated Interferon Lambda (pegIFNë) Phase 2 Dose-Ranging, Active-Controlled Study in Combination With Ribavirin (RBV) for Treatment-Naive HCV Patients (Genotypes 1, 2, 3, or 4): Safety, Viral Response, and Impact of IL28B Host Genotype Through Week 12
11/09/2010
Pharmacokinetics of PEG-Interferon Lambda (pegIFNë) Following Fixed Dosing in Treatment-Naive Hepatitis C Subjects (Single-Dose Interim Data From a Dose-Ranging Phase 2a Study)
11/09/2010
ZymoGenetics Begins Phase 2b Trial of Pegylated Interferon Lambda
6/08/10
Pegylated Interferon Lambda Demonstrates Good Antiviral Activity, May Cause Fewer Side Effects than Interferon Alfa
11/03/09

PSI-879, PSI-938,
PSI-7851, PSI-7977 and PSI-938        TOP
Company Collaboration to Test BMS-790052 + PSI-7977 Combo for Hepatitis C
1-14-2010
Pharmasset Starts Trial of HCV Polymerase Inhibitor PSI-7977 without Interferon
1-11-2011
HCV Polymerase Inhibitor PSI-7977 Receives FDA Fast Track Designation
8/10/2010
Pharmasset Starts New Phase 1b Clinical Trial of HCV Polymerase Inhibitor PSI-938
7/30/2010
Combination of 2 Nucleotide HCV Polymerase Inhibitors, PSI-7977 and PSI-938, Looks Good in Laboratory Study
5/11/2010
Pharmasset Starts Trial of HCV Polymerase Inhibitor PSI-7977 for Genotype 1 Chronic Hepatitis C Patients
1/29/2010
Pharmasset Selects Investigational HCV Polymerase Inhibitor PSI-879 for Preclinical Development
10/09/09
Pharmasset Initiates First Clinical Trial of Second-generation HCV Polymerase Inhibitor PSI-7851
4/10/09
Albumin Interferon (Albuferon) and HCV Polymerase Inhibitor PSI-7851 Advance in Clinical Trials
7/31/09

Danoprevir (RG7227/ITMN-191)        TOP
HCV Protease Inhibitor Danoprevir Promising in Early Trial
6/14/2011
Boosted Danoprevir Improves Response in Prior Null Responders
4/18/2011
Direct-acting Drugs Danoprevir plus RG7128 Suppress HCV without Interferon
10/22/2010
Roche Acquires Rights to InterMune HCV Protease Inhibitor Danoprevir
10/08/2010
Experimental HCV Polymerase Inhibitor RG7128 Is Effective with Standard Therapy in Genotype 2/3 Patients
4/23/2010
HCV Protease Inhibitor Danoprevir (RG7227/ITMN-191) Shows Antiviral Activity at Lower Doses When Boosted with Ritonavir
4/20/2010
Vertex, InterMune, and Idenix Present Hepatitis C Drug Development Updates at Investor Conference
1/22/2010
Pharmasset Announces Continuation of Phase 2b Trial of HCV Polymerase Inhibitor RG7128
12/04/09
Oral HCV Polymerase Inhibitor RG7128 plus Protease Inhibitor RG7227 (ITMN-191) Suppresses HCV Viral Load without Interferon or Ribavirin
11/13/09
InterMune and Roche Begins Trial of Ritonavir-boosted ITMN-191 (RG7227) for Genotype 1 Chronic Hepatitis C Patients
10/06/09
Roche and InterMune Begin Phase 2b Trial of HCV Protease Inhibitor RG7227/ITMN-191
9/04/09
Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09
New Hepatitis C Treatment Trials: HCV Polymerase Inhibitor R7128, Nucleotide Prodrug IDX184, and Albumin Interferon (Albuferon)
1/20/09
HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers
11/14/08
R7128 plus ITMN-191 Perform Well in Laboratory Study; STAT-C Combination Clinical Trial Now Underway
11/14/08
Natural Prevalence of Resistance to HCV Protease Inhibitors
9/25/08
Combination Therapy with Investigational HCV Polymerase Inhibitor R7128 Produces Rapid Response in Patients with Genotype 2/3 HCV
9/12/08

Sorafenib (Nexavar)        TOP
Liver Cancer Drug Sorafenib (Nexavar) Inhibits Hepatitis C Virus Replication in Laboratory Study
1/08/10

SYC-635        TOP
Cyclophilin Inhibitor SYC-635 May Reduce Fibrosis in Addition to Inhibiting Hepatitis C Virus Replication
4/28/10


Telaprevir (Incivek)        TOP

FDA Committee Unanimously Recommends Telaprevir
5-03-2011
FDA Hearings Next Week on Boceprevir and Telaprevir for HCV
4-23-2011
Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
4-5-2011
Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
4-1-2011
HCV Protease Inhibitor Telaprevir Will Get Priority Review in U.S. and Canada
1-25-2011
Vertex Begins Trial of Telaprevir for Treatment-naive Chronic Hepatitis C Patients
10/29/2010
Telaprevir Combination Therapy Boosts Sustained Response Rates for Previously Treated Hepatitis C Patients
9/10/2010
Hope Against Hepatitis C
7/23/2010
75% of Treatment-naive Genotype 1 Hepatitis C Patients Achieve Sustained Response with Telaprevir Combination, Most with 24 Weeks of Therapy
6/08/2010
Many Genotype 1 Hepatitis C Patients Can Be Cured with 24 Weeks of Telaprevir plus Pegylated Interferon/ribavirin
5/14/2010
Telaprevir Monotherapy Is Potent against HCV Genotype 2 but Not 3, Best Results when Combined with Interferon/ribavirin
5/14/2010
Prior Non-responders Achieve Treatment Success with Telaprevir plus Pegylated Interferon and Ribavirin
4/28/2010
Vertex Will Study All-Oral Regimen of HCV Protease Inhibitor Telaprevir plus Polymerase Inhibitor VX-222
3/05/2010
Vertex, InterMune, and Idenix Present Hepatitis C Drug Development Updates at Investor Conference
1/22/2010
HCV Protease Inhibitor Telaprevir Demonstrates Good Efficacy in Both Treatment-experienced and Treatment-naive Patients
11/10/09
Vertex Aims to Receive $250 Million in Milestone Payments for Anti-HCV Drug Telaprevir after Approval in Europe
7/14/09
Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/01/09
Tibotec Begins Enrolling Phase III Study of HCV Protease Inhibitor Telaprevir for Hepatitis C Patients with Prior Treatment Failure
10/24/08
Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study
7/22/08


TMC435        TOP

Interim Results Show TMC435 Works Well in Treatment-experienced Hepatitis C Patients
11/30/2010
Early Analysis Finds Good Outcomes with Once-daily Dosing of HCV Protease Inhibitor TMC435
11/15/2010
Efficacy and Safety of TMC435 in Combination With Peginterferon a-2a and Ribavirin in Treatment-naïve Genotype-1 HCV Patients: 24-Week Interim Results from the PILLAR Study
11/15/2010
In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters
11/15/2010
Virologic analysis of genotype-1-infected patients treated with once-daily TMC435 during the Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA)-1 study
11/15/2010
A Phase IIa, open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6
11/15/2010
Pharmacokinetic-pharmacodynamic analyses of TMC435 in patients infected with hepatitis C virus genotypes 2–6
11/15/2010
Protease Inhibitor TMC435 Shows Potent and Sustained Efficacy for Genotype 1 Chronic Hepatitis C
8/24/2010
Investigational HCV Inhibitor TMC435 Demonstrates Promising Safety and Efficacy in Phase 1 Study
4/02/2010
Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09
OPERA-1 trial (Study TMC435-C201): interim analysis of safety and antiviral activity of TMC435 in treatment-na´ve genotype-1 HCV patients
5/01/09
Antiviral activity and safety of TMC435 combined with peginterferon -2a and ribavirin in patients with genotype-1 hepatitis C infection who failed previous IFN-based therapy
5/01/09
Experimental HCV Protease Inhibitor TMC435350 Demonstrates Favorable Safety and Efficacy in Phase 2a Trial
11/11/08
Experimental HCV Protease Inhibitor TMC435350 Demonstrates Promising Activity and Tolerability in Early Clinical Trial
5/13/08

VCH-759, VCH-916, VCH-222        TOP
Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09
Vertex Acquires VCH-222 and VCH-759, Two Experimental Oral HCV Polymerase Inhibitors
3/15/09
Naturally Occurring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-naive Hepatitis C Patients
1/09/09
Natural Prevalence of Resistance to HCV Protease Inhibitors
9/25/08

Viramidine (Taribavirin)        TOP
Weight-based Taribavirin Works as Well as Ribavirin for Chronic Hepatitis C, but Causes Less Anemia
10/01/2010
Vertex, InterMune, and Idenix Present Hepatitis C Drug Development Updates at Investor Conference
1/22/2010
Viramidine Fails to Show Non-inferiority to Ribavirin at Tested Doses, but Causes Less Anemia
1/19/2010
Prodrug Taribavirin Produces Equivalent Response, but Less Anemia than Ribavirin at 48 Weeks
12/02/08
Taribavirin Efficacy Similar to Ribavirin in Combination Therapy for Hepatitis C, but with Less Anemia
5/09/08
Valeant Reports Promising 12-week Phase IIb Data on Taribavirin
4/01/08






 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 Google Custom Search
 
Experimental Treatments
Treatment Guidelines

HCV Articles by Topic

Cirrhosis
Fibrosis
Hepatocellular Carcinoma
Liver Transplantation
Liver Biopsy

Steatosis
Anemia
Children / Infants / Women
Drug Abuse
Experimental Treatments
FAQs About Hepatitis C
Genotypes
Insulin Resistance / Diabetes
Sustained Viral Response (SVR)
Tests for HCV
Vaccines for HCV